China, already gaining speed in biotechnology, is looking to further accelerate novel drug development by reducing the time ...

U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data ...

The sky-high tariffs imposed by the United States and retaliatory tariffs by China and some other countries hurt global stock ...

Recent federal actions could derail decades of progress. Meanwhile China has prioritized investment in biotech.

China's biotechnology sector is experiencing notable growth, with the ChinaAMC Hang Seng Biotech ETF, tracking the Hang Seng ...

China’s biotechnology stocks have shaken off a four-year slump to be among the hottest performers in Asia this year and funds ...

BEIJING -- China's industrial sector continued its recovery trend in the first four months of 2025, with accelerated profit growth, driven by robust performance in new growth areas such as equipment ...

The recent uptick in the performance of A-share and Hong Kong-listed biotech stocks, particularly those related to innovative drugs, mirrors the trend toward a faster internationalization of China's ...

Photo: Qu Dacheng, Vice Mayor of Chaoyang District, delivers remarks at the Global Investment Cooperation Trends Forum ...

Citing “a substantial rise in trade barriers’’ but without mentioning Trump by name, the 189-country lender predicted that ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech', 6990.HK) today announced that results from its ...

China has leaped from fast follower to global pioneer in drug discovery and development. We believe that Chinese companies ...